Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2020 Nov 11;20(1):161–172. doi: 10.1158/1535-7163.MCT-20-0654

Figure 4. PLK1 and/or NOTCH inhibition in SK-MEL-2 melanoma cells via small molecule inhibitors leads to differential expression of genes as measured using RNA-seq analysis.

Figure 4.

A, MA (log ratio - mean average) plot of all genes. Plots of gene expression against fold change for all genes affected by BI 6727, MK-0752, the combination of the two drugs (BI+MK), as well as the interaction of the two drugs (BI:MK). The differentially expressed genes (DEGs) are depicted as red dots, while the non-DEGs are depicted as gray dots. In each plot, two horizontal lines are drawn to represent |log2 fold change| =1. B, Venn diagram summarizing the relationships between the DEGs for each treatment. The diagram depicts the DEGs with |log2 fold change| ≥1 in each treatment group and their overlap. C, Heatmap of top 100 most significant DEGs with |log2 fold change| ≥1 in the treatment of BI+MK. The fold change for BI 6727 and MK-0752 single drug treatment, as well as the type of each gene, are also displayed.